Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations

Annals of Neurology

Volumn 49, Issue 6, 2001, Pages 706-711

  Wagner, Kathryn R ^a,b   Hamed, Sherifa ^a   Hadley, Donald W ^b   Gropman, Andrea L ^c   Burstein, Aaron H ^d   Escolar, Diana M ^e   Hoffman, Eric P ^a   Fischbeck, Kenneth H ^f  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; GENTAMICIN;

ADOLESCENT; ADULT; ARTICLE; BECKER MUSCULAR DYSTROPHY; CASE REPORT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; HUMAN; MALE; MUSCLE BIOPSY; NEPHROTOXICITY; NONSENSE MUTATION; OTOTOXICITY; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; STOP CODON;

ADOLESCENT; BIOPSY; BLOTTING, WESTERN; CHILD; CODON, NONSENSE; CREATINE KINASE; DYSTROPHIN; GENTAMICINS; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PHENOTYPE; TREATMENT OUTCOME;

EID: 0034982292     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.1023     Document Type: Article

References (35)

1. Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene
2. Intragenic deletions in 21 Duchenne muscular dystrophy (DMD)/Becker muscular dystrophy (BMD) families studied with the dystrophin cDNA: Location of breakpoints on HindIII and Bg/II exon-containing fragment maps, meiotic and mitotic origin of mutations
3. Further studies of gene deletions that cause Duchenne and Becker muscular dystrophies
4. Duplicational mutation at the Duchenne muscular dystrophy locus: Its frequency, distribution, origin and phenotype/genotype correlation
5. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals
6. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin
7. Membrane organization of the dystrophin-glycoprotein complex
8. Glycoprotein complex anchoring dystrophin to sarcolemma
9. Spectrum of small mutations in the dystrophin coding region
10. Complete sequence screening of the dystrophin cDNA in Duchenne dystrophy: The most common mutation of the most mutable gene is a novel recurring duplication of exon 2
11. Population screening of common cystic fibrosis mutations
12. Correction of genetic disease by making sense from nonsense
13. Basis for prokaryotic specificity of action of aminoglycoside antibiotics
14. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin
15. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line
16. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations
17. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice
18. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation
19. Dystrophin: The protein product of the Duchenne muscular dystrophy locus
20. Aminoglycosides
21. Pharmacokinetics of once-daily gentamicin dosing in pediatric patients
22. Once-daily aminoglycoside treatment
23. Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: Evidence of failure of dystrophin production in dystrophin component myonuclei
24. Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once-daily aminoglycoside dosing
25. The 87K postsynaptic membrane protein from Torpedo is a protein-tyrosine kinase substrate homologous to dystrophin
26. Codon context effects on nonsense suppression in human cells
27. Translational termination efficiency in mammals is influenced by the base following the stop codon
28. Aminoglycoside suppression at UAG, UAA and UGA codons in Escherichia coli and human tissue culture cells
29. Context effects on misreading and suppression at UAG codons in human cells
30. The 3′ codon context effect on UAG suppressor tRNA is different in E. coli and human cells
31. Sequence specificity of aminoglycoside-induced stop codon readthrough: Potential implications for treatment of Duchenne muscular dystrophy
32. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy